New drug cocktail aims to shrink Hard-to-Treat kidney tumors

NCT ID NCT04981509

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 5 times

Summary

This phase 2 trial is testing whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can safely shrink or stabilize advanced kidney cancer in people with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. The drugs work by cutting off tumor blood supply, blocking cancer growth signals, and boosting the immune system. The study will enroll 65 participants and measure safety, tumor response, and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab, erlotinib, and atezolizumab
What this could lead to: If this combination works, it could offer a new treatment option for people with advanced hereditary or sporadic papillary kidney cancer, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is a small, early-phase trial (65 people) focused on safety and initial effectiveness. The combination may cause significant side effects, and results may not apply to all patients or lead to a standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary leiomyomatosis and renal cell cancer papillary renal cell carcinoma Papillary renal cell carcinoma, sporadic renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA PAPILLARY RENAL CELL CARCINOMA RENAL CELL CARCINOMA SPORADIC PAPILLARY RENAL CELL CARCINOMA STAGE III RENAL CELL CANCER AJCC V8 STAGE IV RENAL CELL CANCER AJCC V8

Contacts and locations

Locations

Emory Saint Joseph's Hospital
RECRUITING

Atlanta, Georgia, 30342, United States
Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
ACTIVE_NOT_RECRUITING

New York, New York, 10016, United States
NCI - Center for Cancer Research
RECRUITING

Bethesda, Maryland, 20892, United States
NYU Langone Hospital - Long Island
ACTIVE_NOT_RECRUITING

Mineola, New York, 11501, United States
National Institutes of Health Clinical Center
SUSPENDED

Bethesda, Maryland, 20892, United States
Northwestern University
SUSPENDED

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center
SUSPENDED

Columbus, Ohio, 43210, United States
Rutgers Cancer Institute of New Jersey
SUSPENDED

New Brunswick, New Jersey, 08903, United States
UC San Diego Moores Cancer Center
SUSPENDED

La Jolla, California, 92093, United States
UPMC Hillman Cancer Center
SUSPENDED

Pittsburgh, Pennsylvania, 15232, United States
UT MD Anderson Cancer Center
SUSPENDED

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.